1. Generics Bulletin

‘Inhalation Is A New Vector Of Growth’ For Amneal As Albuterol Goal Date Gets Closer

The Firm’s Generics Business Saw 14% YoY Growth In The First Half Of 2024

 
• By Urtė Fultinavičiūtė

Amneal continues to grow its complex product portfolio, with multiple biosimilars and injectables launches coming in the near future, giving the firm confidence to raise its guidance.

Person walking on a arrow shaped path
• Source: Shutterstock

After fighting tooth and nail against originator Teva and its ProAir HFA (albuterol sulfate), Amneal is getting ready for the finale of the inhaler saga.

During the recent Q2 FY2024 investor’s call, one of the firm’s co-founders and co-CEOs Chintu Patel said that Amneal’s generic version of albuterol sulfate has a US Food and Drug

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Earnings

More from Business